Nickerson and colleagues [83] suggested that TET2 loss may play a direct role in PCa progression, reporting a discernible reduction in TET2 expression between normal prostate tissue (n = 29) and adjacent tumor tissue (n = 131), and a significant decrease in expression between primary tumors and metastatic tumors (n = 19) (p = 0.001). The gene discussed is TET2; the disease is neoplasm.